Morfelden Walldorf

Researchers are studying male individuals with haemophilia A who have developed inhibitors to factor VIII replacement treatments. The study aims to observe different management approaches for these patients, focusing on immune tolerance induction ITI methods and evaluating their safety and effectiveness, including the combination of factor VIII and emicizumab. This is an international, multicenter, observational study where participants are followed for up to five years. Participants are grouped based on their treatment one group receives ITI with Nuwiq, octanate, or wilate along with clotting agents as needed a second group receives the same ITI treatment combined with emicizumab prophylaxis and clotting agents as needed and a third group receives routine prophylaxis with emicizumab, aPCC, or rFVIIa without ITI, using clotting agents as necessary for bleeding or surgery. Treatments are given via intravenous or subcutaneous injections according to clinical discretion. During the study, participants undergo regular monitoring of inhibitor levels, factor VIII recovery, half-life, and bleeding frequency. Researchers assess treatment outcomes such as time to achieve immune tolerance, bleeding severity, adverse reactions, thrombotic events, and treatment costs over the five-year observation period. Participants health and treatment responses are closely followed to gather comprehensive data on current management strategies for haemophilia A with inhibitors.